Bellvitge University Hospital, Barcelona, Spain.
Thromb Res. 2013;132(6):652-8. doi: 10.1016/j.thromres.2013.09.019. Epub 2013 Sep 26.
The CRUSADE bleeding risk score (CBRS) accurately predicts major bleeding in non-ST segment elevation myocardial infarction NSTEMI patients. However, little information exists about its application in ST segment elevation myocardial infarction STEMI. We aimed to assess the ability of CBRS to predict in-hospital major bleeding in STEMI patients undergoing primary percutaneous coronary intervention (PPCI).
We prospectively analyzed consecutive STEMI patients undergoing PPCI. Baseline characteristics, in-hospital complications and mid term mortality were recorded. Major bleeding was defined by the CRUSADE definition. Predictive ability of the CBRS was assessed by logistic regression method and the area under the ROC curve (AUC).
We included 1064 patients (mean age 63years). Mean CBRS value was 24. Most of patients (740/1064 (69.6%)) were in the two lowest risk quintiles of CBRS. Incidence of in-hospital major bleeding was 33/1064 (3.1%). The rates of in-hospital bleeding across the quintiles of risk groups were 0.4% (very low risk), 2.6% (low), 4.6% (moderate), 7.2% (high), and 13.4% (very high) (p 0.001). AUC was 0.80 (95% CI 0.73-0.87 p 0.001). In patients with radial access angiography (n=621) AUC was 0.81 (95% CI: 0.65-0.97). Mean follow up was 344days. Patients with bleeding events had higher mortality during follow up (HR 6.91; 95% CI 3.72-12.82; p 0.001).
Our patients had a significantly lower bleeding risk as compared to CRUSADE NSTEMI population. CBRS accurately predicted major in-hospital bleeding in this different clinical scenario, including patients with radial artery approach.
CRUSADE 出血风险评分(CBRS)能准确预测非 ST 段抬高型心肌梗死(NSTEMI)患者的大出血风险。然而,其在 ST 段抬高型心肌梗死(STEMI)患者中的应用信息较少。我们旨在评估 CBRS 预测行直接经皮冠状动脉介入治疗(PPCI)的 STEMI 患者住院期间主要出血的能力。
我们前瞻性分析了连续行 PPCI 的 STEMI 患者。记录基线特征、住院期间并发症和中期死亡率。主要出血根据 CRUSADE 定义。采用逻辑回归法和 ROC 曲线下面积(AUC)评估 CBRS 的预测能力。
我们纳入了 1064 例患者(平均年龄 63 岁)。平均 CBRS 值为 24。大多数患者(740/1064(69.6%))处于 CBRS 两个最低风险五分位数。住院期间主要出血发生率为 33/1064(3.1%)。风险组五分位数的住院出血率分别为 0.4%(极低危)、2.6%(低危)、4.6%(中危)、7.2%(高危)和 13.4%(极高危)(p<0.001)。AUC 为 0.80(95%CI 0.73-0.87,p<0.001)。在接受桡动脉血管造影的患者(n=621)中,AUC 为 0.81(95%CI:0.65-0.97)。平均随访时间为 344 天。随访期间有出血事件的患者死亡率更高(HR 6.91;95%CI 3.72-12.82;p<0.001)。
与 CRUSADE NSTEMI 人群相比,我们的患者出血风险显著降低。CBRS 在这一不同的临床环境中准确预测了住院期间的主要出血,包括接受桡动脉入路的患者。